We are live on ! Find out more
MIM

MetLife Investment Management Portfolio holdings

AUM $19.6B
1-Year Est. Return 32.64%
This Fund
S&P 500
This Quarter Est. Return
-3.28%
1 Year Est. Return
+32.64%
3 Year Est. Return
+107.14%
5 Year Est. Return
+140.16%
10 Year Est. Return
–
AUM
$15.4B
AUM Growth
+$3.25B
Cap. Flow
+$3.84B
Cap. Flow %
24.9%
Top 10 Hldgs %
24.83%
Holding
2,819
New
321
Increased
2,347
Reduced
46
Closed
92

Top Buys

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$246M
2
MSFT icon
Microsoft
MSFT
+$216M
3
AMZN icon
Amazon
AMZN
+$130M
4
TSLA icon
Tesla
TSLA
+$79.6M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$73.3M

Top Sells

Rank Stock Value
1
LQD icon
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
+$49.3M
2
INFO
IHS Markit Ltd. Common Shares
INFO
+$11.7M
3
XLNX
Xilinx Inc
XLNX
+$11.6M
4
AGG icon
iShares Core US Aggregate Bond ETF
AGG
+$5.56M
5
CONE
CyrusOne Inc Common Stock
CONE
+$5.52M

Sector Composition

Rank Sector Weight
1 Technology 23.03%
2 Healthcare 12.21%
3 Financials 12.1%
4 Consumer Discretionary 11.41%
5 Industrials 8.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JXN icon
2751
Jackson Financial
JXN
$8.85B
– –
-4,462
Closed -$187K
KOPN icon
2752
Kopin
KOPN
$933M
– –
-27,436
Closed -$112K
LCTX icon
2753
Lineage Cell Therapeutics
LCTX
$278M
– –
-49,379
Closed -$121K
LMNR icon
2754
Limoneira
LMNR
$251M
– –
-6,067
Closed -$91K
LXRX icon
2755
Lexicon Pharmaceuticals
LXRX
$1.05B
– –
-25,604
Closed -$101K
OLMA icon
2756
Olema Pharmaceuticals
OLMA
$913M
– –
-9,573
Closed -$89.6K
ORIC icon
2757
Oric Pharmaceuticals
ORIC
$1.43B
– –
-11,317
Closed -$166K
PASG icon
2758
Passage Bio
PASG
$14.8M
– –
-537
Closed -$68.1K
PGEN icon
2759
Precigen
PGEN
$2.45B
– –
-13,296
Closed -$49.3K
PLRX icon
2760
Pliant Therapeutics
PLRX
$66.3M
– –
-9,508
Closed -$128K
POWL icon
2761
Powell Industries
POWL
$7.58B
– –
-9,924
Closed -$97.6K
QMCO icon
2762
Quantum Corp
QMCO
$864M
– –
-270
Closed -$29.8K
QNCX icon
2763
Quince Therapeutics
QNCX
$31.8M
– –
-36
Closed -$91K
RCEL icon
2764
Avita Medical
RCEL
$251M
– –
-10,458
Closed -$125K
RNAC icon
2765
Cartesian Therapeutics
RNAC
$262M
– –
-1,203
Closed -$118K
SGC icon
2766
Superior Group of Companies
SGC
$213M
– –
-4,332
Closed -$95K
SMSI icon
2767
Smith Micro Software
SMSI
$17M
– –
-413
Closed -$81.2K
SPRO icon
2768
Spero Therapeutics
SPRO
$68.9M
– –
-9,977
Closed -$160K
STXS icon
2769
Stereotaxis
STXS
$139M
– –
-19,595
Closed -$121K
TCRT icon
2770
Alaunos Therapeutics
TCRT
$4.88M
– –
-81
Closed -$13.2K
TLYS icon
2771
Tilly's
TLYS
$121M
– –
-8,237
Closed -$133K
TRML
2772
DELISTED
Tourmaline Bio
TRML
– –
-976
Closed -$149K
TSAT icon
2773
Telesat
TSAT
$934M
– –
-5,120
Closed -$147K
TSHA icon
2774
Taysha Gene Therapies
TSHA
$2.05B
– –
-9,509
Closed -$111K
UDMY
2775
DELISTED
Udemy
UDMY
– –
-6,474
Closed -$127K
109 110
111
112 113

Similar funds

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
BG
Bahl & Gaynor Cincinnati, Ohio $19.8B AUM 19.53% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HHII
H&H International Investment Palo Alto, California $20B AUM 9.66% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

MetLife Investment Management's Q1 2022 Portfolio in Review

As of Q1 2022, MetLife Investment Management held 2,819 positions worth $15.4B, up 27% from $12.2B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

MetLife Investment Management deployed $3.84B of net new capital in Q1 2022, opening 321 new positions and adding to 2,347 existing holdings. Its largest new stake was iShares Russell 1000 Growth ETF: 519,200 shares worth $36M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was iShares iBoxx $ Investment Grade Corporate Bond ETF, an estimated $49.3M trimmed.

  • MetLife Investment Management's largest Q1 2022 buy was iShares Russell 1000 Growth ETF: 519,200 shares worth $36M.
  • MetLife Investment Management added most to Apple in Q1 2022, an estimated $246M increase.
  • MetLife Investment Management's biggest Q1 2022 reduction was iShares iBoxx $ Investment Grade Corporate Bond ETF, cutting an estimated $49.3M.
  • MetLife Investment Management fully exited IHS Markit Ltd. Common Shares in Q1 2022, selling an estimated $11.7M.
  • MetLife Investment Management's ten largest holdings make up 25% of its $15.4B portfolio in Q1 2022.
  • MetLife Investment Management opened 321 new positions and closed 92 in Q1 2022.
  • MetLife Investment Management's portfolio value rose 27% quarter-over-quarter to $15.4B.

Based on MetLife Investment Management's 13F filing for Q1 2022, filed 12 May 2022.